329 related articles for article (PubMed ID: 7909653)
1. Immunity to erythrocytic stages of malarial parasites.
Long CA; Daly TM; Kima P; Srivastava I
Am J Trop Med Hyg; 1994; 50(4 Suppl):27-32. PubMed ID: 7909653
[TBL] [Abstract][Full Text] [Related]
2. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.
Xu H; Hodder AN; Yan H; Crewther PE; Anders RF; Good MF
J Immunol; 2000 Jul; 165(1):389-96. PubMed ID: 10861076
[TBL] [Abstract][Full Text] [Related]
3. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.
Daly TM; Long CA
J Immunol; 1995 Jul; 155(1):236-43. PubMed ID: 7602100
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.
Rotman HL; Daly TM; Long CA
Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045
[TBL] [Abstract][Full Text] [Related]
5. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.
Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL
Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485
[TBL] [Abstract][Full Text] [Related]
6. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.
Hirunpetcharat C; Tian JH; Kaslow DC; van Rooijen N; Kumar S; Berzofsky JA; Miller LH; Good MF
J Immunol; 1997 Oct; 159(7):3400-11. PubMed ID: 9317139
[TBL] [Abstract][Full Text] [Related]
7. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.
Rainczuk A; Scorza T; Spithill TW; Smooker PM
Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453
[TBL] [Abstract][Full Text] [Related]
8. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.
Burns JM; Flaherty PR; Nanavati P; Weidanz WP
Infect Immun; 2004 Oct; 72(10):5605-12. PubMed ID: 15385457
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
Matsumoto S; Yukitake H; Kanbara H; Yamada T
J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
[TBL] [Abstract][Full Text] [Related]
10. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.
Daly TM; Long CA
Infect Immun; 1993 Jun; 61(6):2462-7. PubMed ID: 8363656
[TBL] [Abstract][Full Text] [Related]
11. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.
Charoenvit Y; Majam VF; Corradin G; Sacci JB; Wang R; Doolan DL; Jones TR; Abot E; Patarroyo ME; Guzman F; Hoffman SL
Infect Immun; 1999 Nov; 67(11):5604-14. PubMed ID: 10531206
[TBL] [Abstract][Full Text] [Related]
12. A hybrid multistage protein vaccine induces protective immunity against murine malaria.
Singh B; Cabrera-Mora M; Jiang J; Moreno A
Infect Immun; 2012 Apr; 80(4):1491-501. PubMed ID: 22252877
[TBL] [Abstract][Full Text] [Related]
13. Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.
Rainczuk A; Scorza T; Smooker PM; Spithill TW
Infect Immun; 2003 Aug; 71(8):4506-15. PubMed ID: 12874330
[TBL] [Abstract][Full Text] [Related]
14. Gamma delta T cells function in cell-mediated immunity to acute blood-stage Plasmodium chabaudi adami malaria.
van der Heyde HC; Elloso MM; Chang WL; Kaplan M; Manning DD; Weidanz WP
J Immunol; 1995 Apr; 154(8):3985-90. PubMed ID: 7706737
[TBL] [Abstract][Full Text] [Related]
15. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.
Daly TM; Long CA
Infect Immun; 1996 Jul; 64(7):2602-8. PubMed ID: 8698485
[TBL] [Abstract][Full Text] [Related]
16. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
Petritus PM; Burns JM
J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
[TBL] [Abstract][Full Text] [Related]
17. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
Wang L; Goschnick MW; Coppel RL
Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
[TBL] [Abstract][Full Text] [Related]
19. Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection.
Peng X; Keitany GJ; Vignali M; Chen L; Gibson C; Choi K; Huang F; Wang R
J Immunol; 2014 Aug; 193(3):1268-77. PubMed ID: 24958899
[TBL] [Abstract][Full Text] [Related]
20. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
